Quantum Biopharma ( (TSE:QNTM) ) has shared an update.
On February 26, 2025, Quantum BioPharma announced the successful completion of its Phase 1 clinical trial for Lucid-21-302, a novel treatment for multiple sclerosis. The trial results showed that the drug was well-tolerated with no safety concerns, marking a significant milestone for the company as it prepares for Phase 2 trials. This advancement positions Quantum BioPharma as a promising player in the MS treatment landscape, potentially benefiting stakeholders through future drug approval and commercialization.
More about Quantum Biopharma
Quantum BioPharma is a biopharmaceutical company focused on developing innovative solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company, through its subsidiary Lucid Psycheceuticals Inc., is advancing its lead compound Lucid-MS, which aims to prevent and reverse myelin degradation in multiple sclerosis. Quantum BioPharma also retains a strategic investment portfolio and has a stake in Celly Nutrition Corp., which markets the OTC product unbuzzd.
YTD Price Performance: 37.50%
Average Trading Volume: 2,467,599
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $10.56M
For an in-depth examination of QNTM stock, go to TipRanks’ Stock Analysis page.